ALK B ALK-abello A/S Class B

ALK – Finanskalender for regnskabsåret 2021

ALK – Finanskalender for regnskabsåret 2021

Finanskalender 2021 for ALK ( / OMX: ALK B / AKABY / AKBLF):

Stilleperiode13. januar 2021


Offentliggørelse af årsrapport 2020

10. februar 2021


Ordinær generalforsamling

ALK

Bøge Allé 1

2970 Hørsholm





Indkomne forslag til dagsordenen for den

ordinære generalforsamling, der er modtaget

af selskabet senest den 3. februar 2021,

vil blive optaget på dagsordenen

(kan fremsættes på





18. marts 2021

kl. 16.00


Stilleperiode

7. april 2021


Delårsrapport 1. kvartal (Q1) 2021

5. maj 2021


Stilleperiode

14. juli 2021


Delårsrapport 1. halvår (Q2) 2021

11. august 2021


Stilleperiode

14. oktober 2021


Delårsrapport 9 måneder (Q3) 2021

11. november 2021



                                             ALK-Abelló A/S



For yderligere oplysninger kontakt venligst:

Investor Relations: Per Plotnikof, tlf. , mobil

Presse: Jeppe Ilkjær, mobil



Om ALK

ALK er en global, specialiseret medicinalvirksomhed med fokus på allergi og allergisk astma. Virksomheden markedsfører allergi-immunterapi og andre produkter og serviceydelser til mennesker med allergi og allergilæger. Virksomheden har hovedkvarter i Hørsholm, beskæftiger omkring 2.400 mennesker over hele verden og er noteret på Nasdaq Copenhagen. Find mere information på



Vedhæftet fil



EN
17/12/2020

Underlying

ALK BALK-abello A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-abello A/S Class B

Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Expecting solid start to the year

We expect a solid Q1 report, with likely c11% organic growth as well as good margin progress supporting the 2025 guidance. Based on its footprint, we see minimal effect in case of tariffs on pharmaceuticals, with the biggest risk coming from potential reciprocal ones from Europe. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
04/25/25 April 25, 2025 1 EN
Free Trial
ALK B ALK-abello A/S ...

Alk-Abello A S: 1 director

A director at Alk-Abello A S bought 1,606 shares at 155.680DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

ALK B ALK-ABELLO A/S CLASS B
02/24/25 February 24, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Sales trump one-offs in Q4

While one-off costs took the initial focus (albeit broadly pre-warned), a solid underlying performance in Q4 was anchored in the important European tablet sales, which exceeded expectations. We find the 2025 guidance in line with expectations, but see upside risk to consensus on the top line given strong momentum in tablet sales in Europe. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
02/19/25 February 19, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Expecting strong year end

We expect a strong Q4, with c12% organic revenue growth YOY, but the EBIT margin to be under pressure from well flagged one-offs related to optimisation initiatives and revision of its Chinese plans. We expect the 2025 guidance to be in line with expectations and its long-term strategy announced last year for >10% organic revenue growth and a c25% EBIT margin. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
02/13/25 February 13, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Solid momentum reaffirmed

We find ALK’s solid momentum reaffirmed with the strong Q3 results, where higher European tablet sales more than offset the softness in SCIT/SLIT-drops. We believe the results also confirmed continued profitability improvement, leaving ALK on track to meet its 2025 EBIT margin target of c25% and in a position of strength to invest in growth opportunities, with the Neffy deal as a good example. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
11/14/24 November 14, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch